Adiuvo Investments S.A.
ADV.WA
Warsaw Stock Exchange0.44
PLN
- -
- -
Adiuvo Investments S.A.
ADV.WA
(Warsaw Stock Exchange)
Recent
price
0.44
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Adiuvo Investments S.A. (ADV.WA) is a venture capital firm that specializes in incubation, seed, startup, early venture, and growth capital investments in the life sciences sector; it focuses on projects in medical devices, biomedical technologies, digital health solutions, nutraceuticals including functional foods, and related biomedical innovations. The firm engages in the selection, development, financing, and commercialization of these innovative projects, primarily targeting opportunities in Poland while supporting research and development conducted in various countries through laboratories and clinical studies worldwide; it typically holds investments for three to five years and makes balance sheet investments. Founded in 2013 and headquartered at ul. Szara 10 in Warsaw, Poland, the company operates in the healthcare industry with a small team of approximately five full-time employees and maintains a portfolio of projects addressing preventive health measures, patient engagement, and treatment participation. In recent developments, Adiuvo Investments S.A. entered accelerated arrangement proceedings in 2024, with a court-appointed judicial supervisor overseeing operations; the company secured bridge financing from an industry partner to support its activities during this restructuring phase, now operating as Adiuvo Investments S.A. w Restrukturyzacji. It continues discussions with industry partners for commercialization of solutions from its portfolio companies, including past advancements like Biovo Technologies Ltd. (a subsidiary of AirwayMedix S.A.) conducting clinical trials for the Cuffix device in a leading U.S. hospital as of late 2021, amid ongoing efforts to advance digital health and nutraceutical initiatives. Recent financial reports indicate revenue of PLN 334,000 and a net loss of PLN 1.03 million for 2024, with quarterly earnings updates through September 2025 reflecting persistent operational challenges in the biomedical investment space.